Charles Schwab
BBOT icon

Charles Schwab’s BridgeBio Oncology BBOT Stock Holding History

Charles Schwab’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Sell
286,518
-4,288
-1% -$35.8K ﹤0.01% 2764
2026
Q1 		$2.6M Buy
290,806
+11,760
+4% +$126K ﹤0.01% 2638
2025
Q4 		$3.49M Sell
279,046
-304
-0.1% -$3.68K ﹤0.01% 2586
2025
Q3 		$3.23M Buy
+279,350
New +$2.91M ﹤0.01% 2610

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Charles Schwab's BBOT Position: Q2 2026 in Review

Charles Schwab reduced its BridgeBio Oncology (BBOT) stake by 1.5% in Q2 2026, selling an estimated $35.8K and leaving 286,518 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

Charles Schwab first reported a position in BBOT in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.49M in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Charles Schwab held 286,518 shares of BridgeBio Oncology worth $2.18M as of Q2 2026.
  • Charles Schwab sold 4,288 BridgeBio Oncology shares in Q2 2026, an estimated $35.8K.
  • BridgeBio Oncology made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2764 holding.
  • Charles Schwab first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 4 quarters since.
  • Charles Schwab's BridgeBio Oncology position peaked at $3.49M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.